Stock LBPH LONGBOARD PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Longboard Pharmaceuticals, Inc.

Equities

LBPH

US54300N1037

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
19.72 USD +2.44% Intraday chart for Longboard Pharmaceuticals, Inc. +13.07% +227.03%
Mar. 26 Longboard Pharmaceuticals, Inc. announced that it has received $59.85 million in funding CI
Mar. 18 Longboard Pharmaceuticals, Inc.(NasdaqGM:LBPH) added to S&P Pharmaceuticals Select Industry Index CI

Business Summary

Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for neurological diseases. The Company is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). It is focused on developing various product candidates in its pipeline, which includes bexicaserin (LP352) and LP659. The Company plans to advance bexicaserin (LP352), an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with no observed impact on 5-HT2B and 5-HT2A receptor subtypes, into a global Phase 3 program. It is also evaluating LP659, an oral, centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, which is in development for the potential treatment of rare neuroinflammatory conditions. The Company is conducting a Phase 1 single-ascending dose (SAD) clinical trial for LP659 in healthy volunteers.

Number of employees: 50

Managers

Managers TitleAgeSince
Kevin Lind CEO
 Chief Executive Officer 47 20-01-02
Brandi Roberts DFI
 Director of Finance/CFO 50 20-12-31
Nuggehally Srinivas CTO
 Chief Tech/Sci/R&D Officer - -
Dewey McLin CTO
 Chief Tech/Sci/R&D Officer - -
Chadwick J. Orevillo COO
 Chief Operating Officer - -
Randall Kaye CTO
 Chief Tech/Sci/R&D Officer 62 22-03-20
Julie Baker PRN
 Corporate Officer/Principal - 22-12-31
Gus Cardenas PRN
 Corporate Officer/Principal - -
Anne Danks PRN
 Corporate Officer/Principal - -
Marco Peters PRN
 Corporate Officer/Principal - -

Members of the board

Members of the board TitleAgeSince
Paul Sekhri CHM
 Chairman 66 20-11-30
Phillip Schneider BRD
 Director/Board Member 68 20-11-30
Vincent Aurentz BRD
 Director/Board Member 56 20-01-31
Casey Lynch BRD
 Director/Board Member 50 21-01-31
Kevin Lind CEO
 Chief Executive Officer 47 20-01-02
Corinne Le Goff BRD
 Director/Board Member 58 21-02-28
Jane Tiller BRD
 Director/Board Member 59 21-11-14

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 2,420,755 0 0 92.26 %
Stock B 1 33,607,490 33,241,120 ( 98.91 %) 0

Shareholders

NameEquities%Valuation
RA Capital Management LP
9.147 %
3,073,119 9.147 % 66 M $
Cormorant Asset Management LP
7.004 %
2,353,141 7.004 % 51 M $
Fidelity Management & Research Co. LLC
4.910 %
1,649,503 4.910 % 36 M $
T. Rowe Price International Ltd.
4.843 %
1,626,982 4.843 % 35 M $
Farallon Capital Management LLC
4.645 %
1,560,500 4.645 % 34 M $
HBM Partners AG (Investment Management)
4.012 %
1,347,967 4.012 % 29 M $
POLAR CAPITAL HOLDINGS PLC
2.977 %
1,000,000 2.977 % 22 M $
Ikarian Capital LLC
2.915 %
979,462 2.915 % 21 M $
Integral Health Asset Management LLC
2.679 %
900,000 2.679 % 19 M $
BlackRock Advisors LLC
2.469 %
829,458 2.469 % 18 M $
NameEquities%Valuation
Cormorant Asset Management LP
18.22 %
661,255 18.22 % 14 M $
Farallon Capital Management LLC
17.79 %
645,490 17.79 % 14 M $

Company contact information

Longboard Pharmaceuticals, Inc.

4275 Executive Square Suite 950

92037, La Jolla

+

http://www.longboardpharma.com
address Longboard Pharmaceuticals, Inc.(LBPH)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
19.25 USD
Average target price
42.57 USD
Spread / Average Target
+121.15%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
LONGBOARD PHARMACEUTICALS, INC. Stock Longboard Pharmaceuticals, Inc.
+225.04% 748M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.38% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.36% 95.71B
ARGENX SE Stock argenx SE
+1.69% 22.02B
BIONTECH SE Stock BioNTech SE
-17.01% 20.9B
GENMAB A/S Stock Genmab A/S
-9.30% 17.85B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.21B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.88% 15.52B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.82% 13.86B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.84% 12.04B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. LBPH Stock
  4. Company Longboard Pharmaceuticals, Inc.